Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin as Adjuvant Therapy in RRMS
NCT06812585Phase 2Completed
- Sponsor
- German University in Cairo
- Start
- Apr 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of metformin in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by German University in Cairo. Primary endpoint: Serum Neurofilament Light Chain at 6 months. Started Apr 2022; status: completed.
02
Drugs
metformin
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT06812585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06812585.